中國恆大(03333.HK)清盤人開始執行轉讓CEG股份予盛建
中國恆大(03333.HK)公佈,6月24日,香港法院以書面方式決定並批準撤銷轉讓申請,原定於6月25日召開的撤銷轉讓申請聆訊因而取消。公司及CEG Holdings清盤人將根據命令開始執行由公司轉讓CEG Holdings股份予盛建。
此前,公司及盛建各持有CEG Holdings 50%股權。2022年12月30日,盛建以1美元將CEG Holdings持股轉讓予恆大,轉讓價值大幅低於CEG Holdings當時的價值,該轉讓在英屬維爾京羣島法律下構成遜值交易。
公司股份自2024年1月29日起暫停買賣,並將繼續停牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.